IMUNON
Lawrenceville, United States · Biotechnology · 35 employees
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality
Funding history
- Series at the market offering — $7.0M — Mar 2026
- Series seed — $3.3M — May 2025
- Funding Round — $10.0M — Aug 2024
Recent signals
- Mar 23, 2026: Raised $7.0M in Series at the market offering
- May 28, 2025: Raised $3.3M in Series seed
- Feb 10, 2025: IMUNON Appoints Dr. Douglas V. Faller as Chief Medical Officer
- Aug 16, 2024: Raised $10.0M
See plans & pricing → Track IMUNON’s funding, hiring, and signals — with verified contacts — on Fundz.